Update shared on 18 Nov 2025
Fair value Decreased 8.70%Analysts have lowered their fair value estimate for DiaSorin from approximately EUR 104 to EUR 95. They cite ongoing headwinds and modestly reduced growth forecasts as the rationale for the change.
Analyst Commentary
Recent street research provides a mix of cautious and optimistic perspectives on DiaSorin, with divergent views regarding the company's growth prospects, market exposure, and valuation trajectory.
Bullish Takeaways- Bullish analysts are increasing their conviction in DiaSorin's ability to accelerate growth in 2026. This suggests upside potential for long-term investors.
- There has been an upward revision of the price target by one major institution. This signals confidence in the company’s strategic direction and recovery capacity.
- Growth forecasts, while moderated in the near term, remain positive for the medium term and support constructive views on execution.
- Bearish analysts highlight DiaSorin’s high exposure to the immunodiagnostics market. This makes the company vulnerable to increased competitive pressures and changes in reimbursement policy.
- Several downward price target revisions indicate caution around valuation and potential headwinds impacting near-term performance.
- The maintenance of an Underweight rating from JPMorgan underlines ongoing concerns regarding the company’s ability to navigate its current challenges.
- Execution risks remain top of mind, with some analysts wary of sustained revenue growth given industry dynamics.
Valuation Changes
- Fair Value Estimate: Lowered from approximately €104 to €95, reflecting a decrease of about 9%.
- Discount Rate: Increased slightly from 10.6% to 10.8%, indicating a marginal rise in perceived risk.
- Revenue Growth Forecast: Reduced modestly from 7.3% to 7.1% per year.
- Net Profit Margin Projection: Declined from 20.0% to 19.4%.
- Future P/E Ratio: Decreased from 25.7x to 24.2x, signaling a slight downward adjustment in expected valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.